Radio Logo
Abrir app
Top 100 emisorasPodcastDeporte en directoEn tu zonaGéneros musicalesTemas de emisoras
PodcastsCienciasBiotechTV - News
Escucha gratis este podcast en la aplicación:
BiotechTV - News
radio.es
Sleep timer
Favoritos
Descarga gratuita en la App Store

BiotechTV - News

BiotechTV
CienciasCiencias de la vida
BiotechTV - News
Último episodio

437 episodios

  • BiotechTV - News

    ASCO 2026: Fresh off an IPO, Eikon Therapeutics Chairman & CEO Roger Perlmutter describes the scientific idea behind the company, and walks us through the leading programs

    31/05/2026 | 35 min
    The lead two programs, which target TLR7/8 and PARP1, have data at ASCO and were licensed with the idea of laying the foundation for clinical expertise at Eikon. Another clinical program, a WRN helicase inhibitor, is the first to entirely come out of Eikon's platform. Plus, Dr. Perlmutter's take on being a public company, and his thoughts on China as a medicine cabinet to the world.
  • BiotechTV - News

    ASCO 2026: "The results that we presented from the RASolute 302 trial are unprecedented." - The CEO behind this year's pancreatic cancer breakthrough walks us through the full results and implications

    31/05/2026 | 13 min
    Dr. Mark Goldsmith of Revolution Medicines describes the benefit seen by advanced patients who received the pancreatic cancer pill daraxonrasib vs those in a control group of investigator's choice standard-of-care chemotherapy, and he discusses the medicine's side effect profile. Plus, next steps for this treatment in pancreatic cancer and beyond.
  • BiotechTV - News

    London based Cytospire Therapeutics has announced an $83M series A financing to develop first-in-class pan-gamma delta T-cell engagers - the lead program is an EGFR targeting solid tumors

    05/05/2026 | 16 min
    Co-Founder & CEO Natalie Mount discusses the raise, and explains why she believes gamma delta T-cell engagers have advantages over CD3s. After presenting preclinical data at the recent AACR annual meeting, the lead EGFR program is preparing to go into the clinic.
  • BiotechTV - News

    Replimune's Chairman discusses FDA's polarizing decision to not approve the company's melanoma treatment after a new review. He says they have filed a FOIA request to learn more about FDA's process

    22/04/2026 | 22 min
    Philip Astley-Starke describes the timeline of development of this oncolytic immunotherapy, his impression of FDA's review process and decisions around it, and the status of where the treatment stands today.
  • BiotechTV - News

    Invivyd develops monoclonal antibodies to prevent or treat infectious diseases. This approach could be useful in tamping down the measles outbreaks that have been occurring due to under-vaccination

    22/04/2026 | 22 min
    CSO Robert Allen describes Invivyd's approach and why antibodies can be a good approach, especially as it relates to being resistant to viral evolution. He walks us through the science and some potential use cases.
Más podcasts de Ciencias
Podcasts a la moda de Ciencias
Acerca de BiotechTV - News
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
Sitio web del podcast
CienciasCiencias de la vida

Escucha BiotechTV - News, Coffee Break: Señal y Ruido y muchos más podcasts de todo el mundo con la aplicación de radio.es

Descarga la app gratuita: radio.es

  • Añadir radios y podcasts a favoritos
  • Transmisión por Wi-Fi y Bluetooth
  • Carplay & Android Auto compatible
  • Muchas otras funciones de la app
Abrir app
BiotechTV - News: Podcasts del grupo
Empresa
Información legal
Servicio
Aplicaciones
Redes sociales
Radio España
v8.9.4| © 2007-2026 radio.de GmbH
Generated: 6/1/2026 - 1:54:47 AM
Una empresa deMADSACK